Key result
Long-term sildenafil safely improves symptoms and quality of life in severe canine pulmonary hypertension.
Why the study?
Long-term efficacy and safety of sildenafil therapy in dogs with severe pulmonary hypertension have rarely been reported.
Case Report (n=1)
No
A 7-month-old male Papillon was presented to us with mild dyspnea, cyanosis and a diastolic murmur detected by cardiac auscultation. Echocardiography revealed severe pulmonary arterial hypertension (PH), and administration of 1 mg/kg of oral sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, twice daily was initiated. Exercise capacity, cyanosis, dyspnea and cardiac murmur were improved after therapy for 4 weeks. PCV was remarkably high (74%) after therapy for 3 years, however, increasing the dose of sildenafil decreased this value (60%). Follow-up after therapy for 4 years revealed that treatment with oral sildenafil only continued to provide the dog with an excellent quality of life, without any side effects.
No takes yet. Share an insight, caveat, or question.
TOYOSHIMA et al. (2007) conducted a case report in Pulmonary hypertension (n=1). Sildenafil was evaluated on Clinical symptoms and quality of life. Long-term oral sildenafil therapy for 4 years safely improved clinical signs and maintained an excellent quality of life in a young dog with severe pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: